Merck and Pfizer are discontinuing the Phase III JAVELIN Ovarian PARP 100 study evaluating Bavencio (avelumab) in advanced ovarian cancer, signalling yet more disappointment for the PD-L1 immuno
Our website has served us well over the years, but after five years since the last re-design – during which aesthetic standards have changed and website technology has improved